RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Discovery of the first N-substituted 4 beta-methyl-5-(3-hydroxyphenyl) morphan to possess highly potent and selective opioid delta receptor antagonist activity
Carroll, F., Zhang, LI., Mascarella, S., Navarro, H., Rothman, RB., Cantrell, BE., Zimmerman, DM., & Thomas, J. (2004). Discovery of the first N-substituted 4 beta-methyl-5-(3-hydroxyphenyl) morphan to possess highly potent and selective opioid delta receptor antagonist activity. Journal of Medicinal Chemistry, 47(2), 281-284. https://doi.org/10.1021/jm030419a
A structurally novel opioid 6 receptor selective antagonist has been identified. This compound, (+)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-azabicyclo[3.3.1]- non-7-yl-(1- phenyl-1-cyclopentane)carboxamide [(+)-KF4, (+)4], showed a K-e value of 0.15 nM in the [S-35]GTPgammaS functional assay. (+)-KF4 is also a 6 inverse agonist with an IC50 value of 1.8 nM. To our knowledge, this is the first potent and selective 6 opioid receptor antagonist from the 5-phenylmorphan class of opioids
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
